N-(1-Methyl-1H-pyrazol-3-yl)pivalamide | 1135343-82-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(1-Methyl-1H-pyrazol-3-yl)pivalamide
• 英文别名: 2,2-dimethyl-N-(1-methylpyrazol-3-yl)propanamide
• CAS: 1135343-82-6
• 化学式: C₉H₁₅N₃O
• mdl: MFCD10670296
• 分子量: 181.238
• InChiKey: CCFQADDXGBGERU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(1-Methyl-1H-pyrazol-3-yl)pivalamide 、 丙烯酸乙酯 在 silver hexafluoroantimonate 、 [Cp*RhCl2]2 、 copper diacetate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以96%的产率得到
  参考文献：
  名称：

  Rhodium(III)-Catalyzed Oxidative Olefination of Pyridines and Quinolines: Multigram-Scale Synthesis of Naphthyridinones

  摘要：

  A Rh(III)-catalyzed oxidative olefination of pyridines and quinolines has been achieved. This method has a broad substrate scope and has been applied to the expeditious, multigram-scale synthesis of naphthyridinones.

  DOI：

  10.1021/ol401540k
• 作为产物：
  描述：

  三甲基乙酰氯 、 N-甲基-3-氨基吡唑 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到N-(1-Methyl-1H-pyrazol-3-yl)pivalamide
  参考文献：
  名称：

  Rhodium(III)-Catalyzed Oxidative Olefination of Pyridines and Quinolines: Multigram-Scale Synthesis of Naphthyridinones

  摘要：

  A Rh(III)-catalyzed oxidative olefination of pyridines and quinolines has been achieved. This method has a broad substrate scope and has been applied to the expeditious, multigram-scale synthesis of naphthyridinones.

  DOI：

  10.1021/ol401540k

文献信息

• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090012094A1

  公开（公告）日：2009-01-08

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文介绍了一种包含二芳胺结构特征的化合物。还介绍了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还介绍了使用这种化合物、制药组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Chianelli Donatella

  公开号：US20110053952A1

  公开（公告）日：2011-03-03

  The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-raf or b-raf kinases.

  本发明提供了式(I)的化合物及其制药组合物，它们可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调的激酶活性相关的疾病或症状的方法。在某些实施例中，本发明提供使用这些化合物治疗、改善或预防涉及c-kit、PDGFRα、PDGFRβ、CSF1R、Abl、BCR-Abl、CSK、JNK1、JNK2、p38、p70S6K、TGFβ、SRC、EGFR、trkB、FGFR3、Fes、Lck、Syk、RAF、MKK4、MKK6、SAPK2β、BRK、Fms、KDR、c-RAf或b-RAf激酶异常活化的疾病或症状的方法。
• TETRACYCLIC COMPOUND
  申请人：Yamamoto Junichiro

  公开号：US20110112299A1

  公开（公告）日：2011-05-12

  Provided are a tetracyclic compound represented by the formula (I): [in the formula (I), the formula (A) represents a benzene ring or the like, X represents CH or a nitrogen atom, Q represents —O— or the like, R 1 , R 2 , and R 3 may be the same or different and each represent a hydrogen atom or the like, l, m, and n each represent an integer from one to the maximum substitutable number of substituents, and R 4 and R 5 may be the same or different and each represent a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof, and the like.

  提供的是一个四环化合物，其化学式表示为(I)：[在化学式(I)中，式(A)表示苯环或类似物，X表示CH或氮原子，Q表示-O-或类似物，R1、R2和R3可以相同也可以不同，每个都表示氢原子或类似物，l、m和n每个表示从1到可替代取代基的最大数的整数，R4和R5可以相同也可以不同，每个都表示氢原子或类似物]，或其药学上可接受的盐等。
• US7563894B2
  申请人：——

  公开号：US7563894B2

  公开（公告）日：2009-07-21